SGS North America has announced a significant expansion of its biologics testing capabilities at its Lincolnshire Center of Excellence in Illinois. This move strengthens the company’s presence in the state and positions it to better serve the growing biopharmaceuticals market in the region.

The 60,000 square-foot center in Lincolnshire, Illinois, has been upgraded with new instrumentation and additional scientific expertise specifically for biologics testing. This expansion allows SGS to handle more testing volume, supporting the burgeoning biologics sector in Illinois and the broader Midwest region. The enhanced facility now offers end-to-end biologics testing services, from early-stage development to final product release, all under one roof.

Derick Govender, Head of SGS North America, highlighted the importance of this local expansion: “With the addition of scientific expertise and leading instrumentation at our Lincolnshire site, SGS is bolstering its biologics testing capabilities to better meet the growing demand for large molecule drug products that are supporting rapid advancements in novel drug discovery.”

This expansion in Illinois reflects the state’s growing importance in the biopharmaceutical industry. By investing in enhanced capabilities at its Lincolnshire facility, SGS is not only expanding its own footprint but also contributing to Illinois’ reputation as a hub for biotechnology and pharmaceutical innovation. The move likely brings new high-skilled jobs to the Lincolnshire area, further bolstering the local economy.

For biopharmaceutical companies in Illinois and neighboring states, this expansion offers local access to state-of-the-art testing services, potentially streamlining their development processes and accelerating time-to-market for new biologics products. As the biopharmaceutical industry continues to grow in the Midwest, SGS’s expanded Illinois facility is well-positioned to support this growth, offering crucial services to both established companies and emerging biotech startups in the region.

This investment by SGS North America underscores the company’s commitment to the Illinois market and its recognition of the state’s strategic importance in the evolving landscape of biologics development and testing. As the demand for biologics-based products continues to surge, SGS’s enhanced capabilities in Lincolnshire will play a vital role in supporting innovation and growth in this critical sector of the pharmaceutical industry.

Read the press release

This article was originally published on iBIO NewsBrief. Gain a head start on your day with iBIO NewsBrief. Subscribe to receive top industry headlines delivered straight to your inbox.

X